Prilenia Therapeutics

Prilenia is a clinical-stage biotech company accelerating progress for people affected by Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders.  

Prilenia was founded in 2018 with the purpose of improving the lives of patients and their families by developing treatments for neurodegenerative and neurodevelopmental disorders focused on the registration of pridopidine in Huntington’s Disease and ALS in 2 pivotal clinical trials. 

The company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.